HRP20160415T1 - Inhibitori beta-sekretaze - Google Patents
Inhibitori beta-sekretaze Download PDFInfo
- Publication number
- HRP20160415T1 HRP20160415T1 HRP20160415TT HRP20160415T HRP20160415T1 HR P20160415 T1 HRP20160415 T1 HR P20160415T1 HR P20160415T T HRP20160415T T HR P20160415TT HR P20160415 T HRP20160415 T HR P20160415T HR P20160415 T1 HRP20160415 T1 HR P20160415T1
- Authority
- HR
- Croatia
- Prior art keywords
- disease
- pharmaceutically acceptable
- acceptable salt
- disorder
- image
- Prior art date
Links
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 title 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 14
- 206010012289 Dementia Diseases 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 10
- 208000024827 Alzheimer disease Diseases 0.000 claims 8
- 102100021257 Beta-secretase 1 Human genes 0.000 claims 4
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 4
- 208000010412 Glaucoma Diseases 0.000 claims 4
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 claims 4
- 230000003412 degenerative effect Effects 0.000 claims 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 208000037259 Amyloid Plaque Diseases 0.000 claims 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 claims 2
- 208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010039966 Senile dementia Diseases 0.000 claims 2
- 230000007278 cognition impairment Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000004558 lewy body Anatomy 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 208000018282 ACys amyloidosis Diseases 0.000 claims 1
- 201000000166 CST3-related cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000011325 dry age related macular degeneration Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000003313 weakening effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C313/02—Sulfinic acids; Derivatives thereof
- C07C313/06—Sulfinamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
- C07C331/02—Thiocyanates
- C07C331/14—Thiocyanates having sulfur atoms of thiocyanate groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/687—Unsaturated compounds containing a keto groups being part of a ring containing halogen
- C07C49/697—Unsaturated compounds containing a keto groups being part of a ring containing halogen containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
- C07C49/747—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
- C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/93—Spiro compounds
- C07C2603/94—Spiro compounds containing "free" spiro atoms
Claims (14)
1. Spoj, naznačen time što je prikazan strukturnom formulom koju se bira između:
[image]
[image]
[image]
ili njegova farmaceutski prihvatljiva sol.
2. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi kao medikament.
3. Farmaceutski pripravak, naznačen time što sadrži najmanje jedan spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, u smjesi s farmaceutski prihvatljivim adjuvansom, razrjeđivačem i/ili podlogom.
4. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju poremećaja ili bolesti povezane s BACE1.
5. Spoj, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 4, gdje se poremećaj ili bolest povezanu s BACE1 bira iz skupine koju čine neurodegenerativni poremećaj, slabljenje kognitivnih funkcija, kognitivni deficit, demencija, naznačen time što je za bolest karakteristična proizvodnja β-amiloidnih naslaga ili neurofibrilarnih klupka.
6. Spoj, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 5, gdje se poremećaj ili bolest bira iz skupine koju čine Alzheimerova bolest, trisomija 21 (Downov Sindrom), nasljedno krvarenje u mozgu uz amiloidozu nizozemskog tipa (HCHWA-D), staračka demencija, cerebralna amiloidna angiopatija, degenerativna demencija, demencije miješano vaskularog i degenerativnog podrijetla, demencija povezana s Parkinsonovom bolešću, demencija povezana s progresivnom supranuklearnom paralizom, demencija povezana s kortikobazalnom degeneracijom, Alzheimerova bolest s difuznim Lewyjevim tijelima, suha staračka degeneracija makule (AMD), te glaukom.
7. Spoj, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 6, gdje je poremećaj ili bolest Alzheimerova bolest.
8. Spoj, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 6, gdje je poremećaj ili bolest glaukom.
9. Upotreba spoja u skladu s patentnim zahtjevom 1, ili njegove farmaceutski prihvatljive soli, naznačena time što je spoj namijenjen proizvodnji medikamenta za liječenje poremećaja povezanog s BACE1 kod subjekta.
10. Upotreba spoja u skladu s patentnim zahtjevom 9, ili njegova farmaceutski prihvatljiva sol, gdje se bolest ili poremećaj povezan s BACE1 bira iz skupine koju čine neurodegenerativni poremećaj, slabljenje kognitivnih funkcija, kognitivni deficit, demencija, naznačena time što je za bolest karakteristična proizvodnja β-amiloidnih naslaga ili neurofibrilarnih klupka.
11. Upotreba spoja u skladu s patentnim zahtjevom 10, ili njegova farmaceutski prihvatljiva sol, naznačena time što se poremećaj ili bolest bira iz skupine koju čine Alzheimerova bolest, trisomija 21 (Down Sindrom), nasljedno krvarenje u mozgu uz amiloidozu nizozemskog tipa (HCHWA-D), staračka demencija, cerebralna amiloidna angiopatija, degenerativna demencija, demencije miješano vaskularog i degenerativnog podrijetla, demencija povezana s Parkinsonovom bolešću, demencija povezana s progresivnom supranuklearnom paralizom, demencija povezana s kortikobazalnom degeneracijom, Alzheimerova bolest s difuznim Lewyjevim tijelima, suha staračka degeneracija makule (AMD), te glaukom.
12. Upotreba spoja u skladu s patentnim zahtjevom 11, ili njegova farmaceutski prihvatljiva sol, naznačena time što je bolest ili poremećaj Alzheimerova bolest.
13. Upotreba spoja u skladu s patentnim zahtjevom 11, ili njegova farmaceutski prihvatljiva sol, naznačena time što je bolest ili poremećaj glaukom.
14. Spoj, naznačen time što ga se bira iz skupine koju čine:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
ili njihove soli.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261606786P | 2012-03-05 | 2012-03-05 | |
| EP13710937.7A EP2822930B1 (en) | 2012-03-05 | 2013-03-04 | Inhibitors of beta-secretase |
| PCT/US2013/028796 WO2013134085A1 (en) | 2012-03-05 | 2013-03-04 | Inhibitors of beta-secretase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160415T1 true HRP20160415T1 (hr) | 2016-06-03 |
Family
ID=47902355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160415TT HRP20160415T1 (hr) | 2012-03-05 | 2016-04-20 | Inhibitori beta-sekretaze |
Country Status (40)
| Country | Link |
|---|---|
| US (4) | US8981112B2 (hr) |
| EP (1) | EP2822930B1 (hr) |
| JP (1) | JP6161643B2 (hr) |
| KR (1) | KR20140138774A (hr) |
| CN (1) | CN104271558B (hr) |
| AP (1) | AP4029A (hr) |
| AR (1) | AR090241A1 (hr) |
| AU (2) | AU2013230523B2 (hr) |
| BR (1) | BR112014021269A2 (hr) |
| CA (1) | CA2864143C (hr) |
| CL (1) | CL2014002334A1 (hr) |
| CO (1) | CO7091177A2 (hr) |
| CY (1) | CY1117543T1 (hr) |
| DK (1) | DK2822930T3 (hr) |
| EA (1) | EA024995B1 (hr) |
| EC (1) | ECSP14020640A (hr) |
| ES (1) | ES2568928T3 (hr) |
| HK (1) | HK1205739A1 (hr) |
| HR (1) | HRP20160415T1 (hr) |
| HU (1) | HUE027289T2 (hr) |
| IL (1) | IL233887A (hr) |
| IN (1) | IN2014DN06710A (hr) |
| MA (1) | MA35945B1 (hr) |
| ME (1) | ME02390B (hr) |
| MX (1) | MX353432B (hr) |
| MY (1) | MY171091A (hr) |
| NZ (1) | NZ629239A (hr) |
| PE (1) | PE20141972A1 (hr) |
| PH (1) | PH12014501963B1 (hr) |
| PL (1) | PL2822930T3 (hr) |
| RS (1) | RS54730B1 (hr) |
| SG (1) | SG11201404600VA (hr) |
| SI (1) | SI2822930T1 (hr) |
| SM (1) | SMT201600114B (hr) |
| TN (1) | TN2014000326A1 (hr) |
| TW (1) | TWI557112B (hr) |
| UA (1) | UA113641C2 (hr) |
| UY (1) | UY34654A (hr) |
| WO (1) | WO2013134085A1 (hr) |
| ZA (1) | ZA201405846B (hr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2789684T3 (en) | 2008-05-23 | 2017-02-20 | Siwa Corp | Methods and compositions for facilitating regeneration |
| UY32490A (es) | 2009-03-13 | 2010-10-29 | Boehringer Ingelheim Int | Inhibidores de beta-secretasa |
| EP2539322B1 (en) | 2010-02-24 | 2014-01-01 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
| TWI557112B (zh) | 2012-03-05 | 2016-11-11 | 百靈佳殷格翰國際股份有限公司 | β－分泌酶抑制劑 |
| EP2847177B1 (en) | 2012-05-09 | 2017-10-11 | Boehringer Ingelheim International GmbH | Methods for making oxetan-3-ylmethanamines |
| TW201422592A (zh) * | 2012-08-27 | 2014-06-16 | Boehringer Ingelheim Int | β－分泌酶抑制劑 |
| JP2015532282A (ja) | 2012-09-28 | 2015-11-09 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | β−セクレターゼの阻害剤 |
| US9079832B2 (en) | 2012-11-21 | 2015-07-14 | Boehringer Ingelheim International Gmbh | Process for making N-sulfinyl α-amino amides |
| AR102202A1 (es) * | 2014-10-07 | 2017-02-08 | Astrazeneca Ab | Compuestos de oxazol y su uso como inhibidores de bace de oxazol |
| US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
| US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
| CA3021150C (en) | 2016-02-19 | 2023-02-07 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age) |
| CN109311975A (zh) * | 2016-04-15 | 2019-02-05 | Siwa有限公司 | 用于治疗神经退行性紊乱的抗age抗体 |
| EP3475306A1 (en) | 2016-06-23 | 2019-05-01 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
| US11077108B2 (en) * | 2016-09-07 | 2021-08-03 | The Regents Of The University Of California | Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-tau and improve cognition |
| CA3059803A1 (en) | 2017-04-13 | 2018-10-18 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
| US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
| CN113082209A (zh) * | 2021-03-31 | 2021-07-09 | 中国科学技术大学 | Cd4+t细胞源性bace1、ep2、ep4作为阿尔茨海默病治疗靶点的应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5745185A (en) | 1980-07-21 | 1982-03-13 | Eisai Co Ltd | Hydantoin derivative and its preparation |
| EP0602060A1 (en) | 1991-08-28 | 1994-06-22 | PHARMACIA & UPJOHN COMPANY | Spirocyclic benzopyran imidazolines, their preparation and their use as potassium channel activators |
| CA2189634A1 (en) | 1994-05-06 | 1995-11-16 | John J. Baldwin | Combinatorial dihydrobenzopyran library |
| US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| MXPA06006730A (es) | 2003-12-15 | 2006-08-31 | Schering Corp | Inhibidores de aspartil proteasa heterociclicos. |
| KR20070026811A (ko) | 2004-06-16 | 2007-03-08 | 와이어쓰 | 베타-세크리타제 억제제로서의 디페닐이미다조피리미딘 및디페닐이미다졸 아민 |
| MXPA06014793A (es) | 2004-06-16 | 2007-02-16 | Wyeth Corp | Derivados de amino-5, 5-difenilimidazolona para la inhibicion de ??-secretasa. |
| CA2583342A1 (en) | 2004-10-13 | 2006-04-27 | Merck And Co., Inc. | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer's disease |
| US7759354B2 (en) | 2005-06-14 | 2010-07-20 | Schering Corporation | Bicyclic guanidine derivatives as asparyl protease inhibitors, compositions, and uses thereof |
| CN101198595A (zh) | 2005-06-14 | 2008-06-11 | 先灵公司 | 天冬氨酰基蛋白酶抑制剂 |
| EP1896448A1 (en) | 2005-06-30 | 2008-03-12 | Wyeth | AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION |
| TW200738683A (en) | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
| TW200730523A (en) | 2005-07-29 | 2007-08-16 | Wyeth Corp | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation |
| RU2423568C2 (ru) | 2005-07-29 | 2011-07-10 | Конинклейке Филипс Электроникс Н.В. | Устройство для глажения с паром |
| JP2009509957A (ja) | 2005-09-26 | 2009-03-12 | ワイス | β−セクレターゼ阻害剤としてのアミノ−５−［４−（ジフルオロメトキシ）フェニル］−５−フェニルイミダゾロン化合物 |
| CN101346357B (zh) | 2005-10-25 | 2014-04-02 | 盐野义制药株式会社 | 氨基二氢噻嗪衍生物 |
| US7872009B2 (en) | 2005-11-21 | 2011-01-18 | Amgen Inc. | Beta-Secretase modulators and methods of use |
| DE102005057688A1 (de) | 2005-12-01 | 2007-06-14 | Endress + Hauser Flowtec Ag | Vorrichtung zur Bestimmung und/oder Überwachung des Massedurchflusses eines gasförmigen Mediums |
| CA2634037A1 (en) | 2005-12-19 | 2007-07-12 | Wyeth | 2-amino-5-piperidinylimidazolone compounds and use thereof for .beta.-secretase modulation |
| EP1974278A4 (en) | 2005-12-20 | 2012-01-04 | Fieldbus Foundation | SYSTEM AND METHOD FOR IMPLEMENTING INSTRUMENTED SAFETY SYSTEMS |
| WO2007100536A1 (en) | 2006-02-24 | 2007-09-07 | Wyeth | DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE |
| MX2008015956A (es) | 2006-06-12 | 2009-01-09 | Schering Corp | Inhibidores heterociclicos de aspartil-proteasa. |
| WO2008010481A1 (fr) | 2006-07-18 | 2008-01-24 | Astellas Pharma Inc. | Dérivé d'aminoindane ou sel de celui-ci |
| JP2010502705A (ja) | 2006-09-07 | 2010-01-28 | メルク エンド カムパニー インコーポレーテッド | アルツハイマー病の治療用としてのスピロピペリジンベータセクレターゼ阻害剤 |
| WO2008076044A1 (en) | 2006-12-20 | 2008-06-26 | Astrazeneca Ab | Novel 2-amino-5, 5-diaryl-imidazol-4-ones |
| TW200831091A (en) | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
| TW200831484A (en) | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
| PE20090160A1 (es) | 2007-03-20 | 2009-02-11 | Wyeth Corp | COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA |
| AR065814A1 (es) | 2007-03-23 | 2009-07-01 | Wyeth Corp | Derivados de 5-fenilimidazolona,inhibidores de beta-secretasa,composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar trastornos asociados a niveles beta-amiloides elevados. |
| BRPI0811034A2 (pt) | 2007-04-24 | 2014-12-09 | Shionogi & Co | Derivados de aminodi-hidrotiazina substituídos com um grupo cíclico e seus usos e composições farmacêuticas |
| EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| TW200902503A (en) | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
| EP2077637B1 (en) | 2007-12-12 | 2020-03-11 | Alcatel Lucent | System and method for protecting payload information in radio transmission |
| ES2398017T3 (es) | 2008-02-18 | 2013-03-13 | F. Hoffmann-La Roche Ag | Derivados de 4,5-dihidro-oxazol-2-il-amina |
| TWI431004B (zh) | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Ｂａｃｅ抑制劑 |
| WO2010013794A1 (en) | 2008-07-28 | 2010-02-04 | Eisai R&D Management Co., Ltd. | Spiroaminodihydrothiazine derivatives |
| WO2010013302A1 (ja) | 2008-07-28 | 2010-02-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スピロアミノジヒドロチアジン誘導体 |
| WO2010021680A2 (en) | 2008-08-19 | 2010-02-25 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
| WO2010030954A1 (en) | 2008-09-11 | 2010-03-18 | Amgen Inc. | Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use |
| EA201170722A1 (ru) * | 2008-11-23 | 2011-10-31 | Пфайзер Инк. | Лактамы в качестве ингибиторов бета-секретазы |
| UY32490A (es) * | 2009-03-13 | 2010-10-29 | Boehringer Ingelheim Int | Inhibidores de beta-secretasa |
| WO2011072064A1 (en) | 2009-12-08 | 2011-06-16 | Array Biopharma Inc. | S piro [chroman - 4, 4 ' - imidazol] ones as beta - secretase inhibitors |
| EP2539322B1 (en) * | 2010-02-24 | 2014-01-01 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
| AR080865A1 (es) | 2010-03-31 | 2012-05-16 | Array Biopharma Inc | Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer. |
| US8415483B2 (en) * | 2010-12-22 | 2013-04-09 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
| TWI557112B (zh) | 2012-03-05 | 2016-11-11 | 百靈佳殷格翰國際股份有限公司 | β－分泌酶抑制劑 |
-
2013
- 2013-02-06 TW TW102104519A patent/TWI557112B/zh not_active IP Right Cessation
- 2013-03-04 MY MYPI2014002293A patent/MY171091A/en unknown
- 2013-03-04 UA UAA201410695A patent/UA113641C2/uk unknown
- 2013-03-04 NZ NZ629239A patent/NZ629239A/en not_active IP Right Cessation
- 2013-03-04 US US13/784,032 patent/US8981112B2/en active Active
- 2013-03-04 BR BR112014021269A patent/BR112014021269A2/pt active Search and Examination
- 2013-03-04 SG SG11201404600VA patent/SG11201404600VA/en unknown
- 2013-03-04 JP JP2014560985A patent/JP6161643B2/ja not_active Expired - Fee Related
- 2013-03-04 SI SI201330173A patent/SI2822930T1/sl unknown
- 2013-03-04 MX MX2014010625A patent/MX353432B/es active IP Right Grant
- 2013-03-04 HU HUE13710937A patent/HUE027289T2/en unknown
- 2013-03-04 PL PL13710937.7T patent/PL2822930T3/pl unknown
- 2013-03-04 AU AU2013230523A patent/AU2013230523B2/en not_active Ceased
- 2013-03-04 WO PCT/US2013/028796 patent/WO2013134085A1/en active Application Filing
- 2013-03-04 KR KR1020147026838A patent/KR20140138774A/ko not_active Application Discontinuation
- 2013-03-04 RS RS20160246A patent/RS54730B1/sr unknown
- 2013-03-04 IN IN6710DEN2014 patent/IN2014DN06710A/en unknown
- 2013-03-04 ES ES13710937.7T patent/ES2568928T3/es active Active
- 2013-03-04 EP EP13710937.7A patent/EP2822930B1/en active Active
- 2013-03-04 CA CA2864143A patent/CA2864143C/en not_active Expired - Fee Related
- 2013-03-04 AP AP2014007900A patent/AP4029A/en active
- 2013-03-04 PE PE2014001347A patent/PE20141972A1/es active IP Right Grant
- 2013-03-04 UY UY0001034654A patent/UY34654A/es active IP Right Grant
- 2013-03-04 EA EA201491534A patent/EA024995B1/ru not_active IP Right Cessation
- 2013-03-04 ME MEP-2016-74A patent/ME02390B/me unknown
- 2013-03-04 CN CN201380012529.9A patent/CN104271558B/zh not_active Expired - Fee Related
- 2013-03-04 DK DK13710937.7T patent/DK2822930T3/en active
- 2013-03-05 AR ARP130100706A patent/AR090241A1/es active IP Right Grant
-
2014
- 2014-07-30 IL IL233887A patent/IL233887A/en active IP Right Grant
- 2014-07-31 TN TNP2014000326A patent/TN2014000326A1/fr unknown
- 2014-08-08 ZA ZA2014/05846A patent/ZA201405846B/en unknown
- 2014-09-02 PH PH12014501963A patent/PH12014501963B1/en unknown
- 2014-09-02 CL CL2014002334A patent/CL2014002334A1/es unknown
- 2014-09-26 MA MA37375A patent/MA35945B1/fr unknown
- 2014-09-29 CO CO14215177A patent/CO7091177A2/es unknown
- 2014-09-29 EC ECIEPI201420640A patent/ECSP14020640A/es unknown
-
2015
- 2015-02-04 US US14/613,550 patent/US9526727B2/en active Active
- 2015-06-30 HK HK15106248.0A patent/HK1205739A1/zh not_active IP Right Cessation
-
2016
- 2016-04-19 SM SM201600114T patent/SMT201600114B/it unknown
- 2016-04-19 CY CY20161100327T patent/CY1117543T1/el unknown
- 2016-04-20 HR HRP20160415TT patent/HRP20160415T1/hr unknown
- 2016-12-19 US US15/383,287 patent/US9949975B2/en active Active
-
2017
- 2017-10-02 AU AU2017236042A patent/AU2017236042B2/en not_active Ceased
-
2018
- 2018-03-12 US US15/918,546 patent/US20180344734A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160415T1 (hr) | Inhibitori beta-sekretaze | |
| JP2015511958A5 (hr) | ||
| HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
| MX2017013483A (es) | Compuestos y su uso como inhibidores de ?-secretasa 1 (bace1). | |
| HRP20201216T1 (hr) | PRIPRAVCI I POSTUPCI ZA LIJEČENJE POREMEĆAJA CNS-a | |
| HRP20160185T1 (hr) | Spojevi iminotiadiazin dioksida kao inhibitori bace, smjese i njihova uporaba | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| PH12018500106A1 (en) | Ethynyl derivatives as metabotropic glutamate receptor modulators | |
| HRP20221294T1 (hr) | Neuroaktivni steroidi, njihovi pripravci i uporabe | |
| MY167264A (en) | Bridged piperidine derivatives | |
| SI2875011T1 (en) | 5-HT3 receptor antagonists | |
| RU2013138733A (ru) | Конденсированные производные аминодигидротиазина | |
| WO2012077932A3 (ko) | 신규한 피라졸로 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물 | |
| WO2013174930A3 (en) | 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| HRP20201473T1 (hr) | Inhibitori lizin gingipaina | |
| TW201613890A (en) | Pyridine derivatives as muscarinic M1 receptor positive allosteric modulators | |
| JP2016503010A5 (hr) | ||
| WO2017177004A8 (en) | Tertiary amides and method of use | |
| HRP20140967T1 (hr) | SPOJEVI, PRIPRAVCI I POSTUPCI ZA LIJEÄŚENJE beta-AMILOIDNIH BOLESTI I SINUKLEINOPATIJA | |
| WO2013170072A3 (en) | Compounds for the treatment of neurological disorders | |
| SI3102573T1 (en) | SUBSTITUTED TIAZOL OR OXASOL AS ANTAGONISTS OF THE RECEPTOR P2X7 | |
| WO2013057251A3 (en) | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| PH12019500822A1 (en) | Crystalline forms of eravacycline | |
| HRP20201985T1 (hr) | Piridonski spoj kao c-met inhibitor | |
| WO2016103262A3 (en) | Crystal forms of apomorphine and uses thereof |